EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity

Leda Coelewij, Marsilio Adriani, Pierre Dönnes, Kirsty E Waddington, Coziana Ciurtin, Eva Kubala Havrdova, ABIRISK Consortium, Rachel Farrell, Petra Nytrova, Inés Pineda-Torra, Elizabeth C Jury

Clinical Immunology · 2024

DOI: 10.1016/j.clim.2024.110339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2024. Verfasst von Leda Coelewij und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicine, University College London, London WC1E 6JF, United Kingdom. Hauptthemen laut MEDLINE: Interferon-beta, Transcriptome, Multiple Sclerosis, Relapsing-Remitting, Proteomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Research and Innovation, UKRI MRC, NIHR UCLH BRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-drug antibodies (ADA) reduce the efficacy of immunotherapies in multiple sclerosis (MS) and are associated with increased disease progression risk. Blood biomarkers predicting immunogenicity to biopharmaceuticals represent an unmet clinical need. Patients with relapsing remitting (RR)MS were recruited before (baseline), three, and 12 (M12) months after commencing interferon-beta treatment. Neutralising ADA-status was determined at M12, and patients were stratified at baseline according to their M12 ADA-status (ADA-positive/ADA-negative). Patients stratified as ADA-positive were characterised by an early dampened response to interferon-beta (prior to serum ADA detection) and distinct proinflammatory transcriptomic/proteomic peripheral blood signatures enriched for 'immune response activation' including phosphoinositide 3-kinase-γ and NFκB-signalling pathways both at baseline and throughout the treatment course, compared to ADA-negative patients. These immunogenicity-associated proinflammatory signatures significantly overlapped with signatures of MS disease severity. Thus, whole blood molecular profiling is a promising tool for prediction of ADA-development in RRMS and could provide insight into mechanisms of immunogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon-betaTranscriptomeMultiple Sclerosis, Relapsing-RemittingProteomicsHumansFemaleMaleAdultMiddle AgedSeverity of Illness IndexBiomarkersMultiple Sclerosis

Stichwörter der Autor:innen

Anti-drug antibodiesBiomarkersImmunogenicityMultiple sclerosisProgression

Substanzen

Interferon-betaBiomarkers

Autor:innen und Institutionen

  • Division of Medicine, University College London, London WC1E 6JF, United Kingdom.
  • Division of Medicine, University College London, London WC1E 6JF, United Kingdom; SciCross AB, Skövde, Sweden.
  • Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, 120 00, Czech Republic.
  • Department of Neuroinflammation, University College London, Institute of Neurology and National Hospital of Neurology and Neurosurgery, London WC1N 3BG, United Kingdom.
  • Division of Medicine, University College London, London WC1E 6JF, United Kingdom; Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Parque Científico y Tecnológico Cartuja 93 Avda. Américo Ves…
  • Division of Medicine, University College London, London WC1E 6JF, United Kingdom. Electronic address: e.jury@ucl.ac.uk.

Förderung

  • European Union's Research and Innovation
  • UKRI MRC
  • NIHR UCLH BRC
  • European Geosciences Union
  • Seventh Framework Programme
  • Birkbeck, University of London
  • Innovative Medicines Initiative
  • NIHR Barts Biomedical Research Centre, Queen Mary University of London

Zitieren

APA

Coelewij, L., Adriani, M., Dönnes, P., Waddington, K. E., Ciurtin, C., Havrdova, E. K., ABIRISK Consortium, Farrell, R., Nytrova, P., Pineda-Torra, I., & Jury, E. C. (2024). Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity. Clinical Immunology. https://doi.org/10.1016/j.clim.2024.110339

Vancouver

Coelewij L, Adriani M, Dönnes P, Waddington KE, Ciurtin C, Havrdova EK, et al. Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity. Clinical Immunology. 2024. doi:10.1016/j.clim.2024.110339

BibTeX
@article{Coelewij2024,
  author = {Coelewij, Leda and Adriani, Marsilio and Dönnes, Pierre and Waddington, Kirsty E and Ciurtin, Coziana and Havrdova, Eva Kubala and ABIRISK Consortium, ABIRISK Consortium and Farrell, Rachel and Nytrova, Petra and Pineda-Torra, Inés and Jury, Elizabeth C},
  title = {Patients with multiple sclerosis who develop immunogenicity to interferon-beta have distinct transcriptomic and proteomic signatures prior to treatment which are associated with disease severity},
  journal = {Clinical Immunology},
  year = {2024},
  doi = {10.1016/j.clim.2024.110339}
}
Kostenlos starten →